A growing number of U.S. adolescents, facing record rates of pediatric obesity, are reportedly turning to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (semaglutide).
The update comes when the Danish drugmaker is already struggling to meet the demand from adult patients.
In the first ten months of 2023, 1,268 children aged 12 to 17 diagnosed with obesity initiated Wegovy treatment—marking a significant surge compared to the mere 25 prescriptions in 2022, Reuters reports.
The data, compiled by health technology company Komodo Health, also reveals a parallel trend in Medicaid data from five states, demonstrating an increasing willingness among families to embrace Wegovy.
However, the overall numbers ...